Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Oklahoma Medical Research FoundationFounded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Founded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Publication Number
US-12030950-B2
Publication Date
2024-07-09
Expiration Date
Abstract
The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject.
Core Innovation
The invention provides methods to treat neuromyelitis optica (NMO) and interferon-resistant multiple sclerosis (MS) by inhibiting BAFF and/or APRIL using agents such as atacicept, TACI-Ig, belimumab, blisibimod, and tabalumab. Treatments are described with multiple administration routes [procedural detail omitted for safety] and with repeated or chronic dosing [procedural detail omitted for safety] and pharmaceutical formulations and kits.
The background identifies interferon-resistant MS and TH17-driven disease manifestations analogous to NMO as conditions requiring alternative approaches to type I interferon therapy. Experimental evidence from TH1- and TH17-induced EAE shows TH17-EAE has elevated BAFF and APRIL, neutrophil and B-cell central nervous system infiltration, is worsened by interferon-β, and is ameliorated by TACI-Ig, supporting BAFF/APRIL-targeted therapy for TH17-driven disease.
Claims Coverage
The independent claim recites one main inventive feature for treating interferon-resistant multiple sclerosis.
Administration of atacicept for interferon-resistant multiple sclerosis
A method for treating a subject having interferon-resistant multiple sclerosis comprising administering atacicept to said subject.
The claimed inventive feature is the use of atacicept to treat subjects with interferon-resistant multiple sclerosis.
Stated Advantages
Amelioration of TH17-driven disease as demonstrated by TACI-Ig reducing TH17-induced EAE.
Identification of interferon-resistant MS using a companion diagnostic measuring TH17/granulocyte factors, type I interferons, BAFF and APRIL to enable targeted BAFF/APRIL inhibition.
Documented Applications
Treatment of neuromyelitis optica (NMO) by inhibiting BAFF and/or APRIL.
Treatment of interferon-resistant multiple sclerosis (MS) by inhibiting BAFF and/or APRIL, including administration of atacicept.
A companion diagnostic to identify interferon-resistant MS by measuring TH17/granulocyte factors (for example IL-17A/F, IL-8, Gro-alpha, CXCL5), type I interferons, BAFF and APRIL [procedural detail omitted for safety], and associated kits and formulations.
Combination therapies for BAFF/APRIL inhibition with agents including corticosteroids, Rituximab, elastase inhibitors and gro-alpha inhibitors, and other specified MS therapies.
Interested in licensing this patent?